OTLK (Outlook Therapeutics) Net Margin %: -3,506.30% (As of Mar. 2026)

What is Outlook Therapeutics Net Margin %?

Outlook Therapeutics OTLK -5.06% 11 Net Margin % is -3,506.30% as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 947 Biotechnology companies, Outlook Therapeutics ranks worse than 94.83% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Outlook Therapeutics's Net Income for the three months ended in Mar. 2026 was $-4.45 Mil. Outlook Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.13 Mil. Therefore, Outlook Therapeutics's net margin for the quarter that ended in Mar. 2026 was -3,506.30%.

The historical rank and industry rank for Outlook Therapeutics's Net Margin % or its related term are showing as below:

OTLK' s Net Margin % Range Over the Past 10 Years
Min: -18360.54 Med: -1019.12 Max: -423.82
Current: -18360.54

OTLK's Net Margin % is ranked worse than
94.83% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs OTLK: -18360.54

Outlook Therapeutics (NAS:OTLK) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Outlook Therapeutics Net Margin % Related Terms

Outlook Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Net Margin % Chart

Outlook Therapeutics Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

Net Margin %

Get a 7-Day Free Trial

0.00

-4,414.78

Outlook Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															0.00	-1,339.07	14,448.91	1,908.77	-3,506.30

OTLK vs INO, CBUS, RANI: Net Margin % Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Outlook Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Net Margin % falls into.

Save Embed

11GF Score

Outlook Therapeutics Inc OTLK

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Outlook Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Outlook Therapeutics's Net Margin for the fiscal year that ended in Sep. 2025 is calculated as

Net Margin	=	Net Income (A: Sep. 2025 )	/	Revenue (A: Sep. 2025 )
	=	-62.425	/	1.414
	=	-4,414.78 %

Outlook Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-4.453	/	0.127
	=	-3,506.30 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -3,506.30% mean?

Outlook Therapeutics (OTLK) has a Net Margin % of -3,506.30% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Outlook Therapeutics and its competitors. According to the industry distribution chart, Outlook Therapeutics ranks #898 out of 947 companies in the Biotechnology industry, placing it in the top 94.8%.

Is Outlook Therapeutics' Net Margin % too high?

Outlook Therapeutics' current Net Margin % is -3,506.30%. Based on the distribution chart, Outlook Therapeutics ranks #898 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.

How does Outlook Therapeutics' Net Margin % compare to INO and CBUS?

According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #898 out of 947 companies for Net Margin %. This places Outlook Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current Net Margin % is -3,506.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Outlook Therapeutics stock overvalued right now?

Outlook Therapeutics (OTLK) has a current Net Margin % of -3,506.30%. The current Net Margin % is -3,506.30%. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Net Margin % is -3,506.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies INO CBUS RANI CGTX ALDX PEPG COYA SEER VANI PYXS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 41O:Germany

Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852

Website https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

11GF Score

Get the complete analysis for OTLK

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60

Price

View OTLK Analysis

See Net Margin % data for all stocks →